StockNews.AI
CRDF
StockNews.AI
126 days

Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

1. Cardiff Oncology granted 35,040 stock options to a new employee. 2. Options have an exercise price of $2.79, equal to recent closing price. 3. Stock options vest over four years, encouraging employee retention. 4. Cardiff focuses on PLK1 inhibition for cancer therapies like onvansertib. 5. Ongoing trials target various cancer types, indicating growth potential.

4m saved
Insight
Article

FAQ

Why Neutral?

The stock option grant is standard practice and does not materially change fundamentals. Similar announcements in biotech typically result in minimal immediate market reactions.

How important is it?

While the employee option grant is significant, it lacks immediate influence on company valuations. Its role in employee retention may support long-term growth.

Why Short Term?

Stock options are relevant for short-term employee alignment; long-term effects depend on product success. Retention incentives may stabilize the workforce.

Related Companies

VRTXCLDXONCE
SAN DIEGO, April 15, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that on April 14, 2025, non-qualified stock option awards to purchase an aggregate of 35,040 shares of its common stock were granted to one new employee. The stock options were granted as inducements material to the new employee becoming an employee of Cardiff Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $2.79 per share, which is equal to the closing price of Cardiff Oncology's common stock on April 14, 2025. Each option will vest over a 4-year period, with 25% of the shares vesting upon the 1-year anniversary of the date of grant and the remaining shares vesting monthly over the following 36-months, subject to the employee's continued employment with Cardiff Oncology on such vesting dates. About Cardiff Oncology, Inc. Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard of care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC), as well as in ongoing and planned investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC) and triple negative breast cancer (TNBC). These programs and the Company's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit https://www.cardiffoncology.com.  Cardiff Oncology Contact:James LevineChief Financial Officer858-952-7670jlevine@cardiffoncology.com  Investor Contact:Kiki Patel, PharmDGilmartin Group332-895-3225kiki@gilmartinir.com  Media Contact:Michael LaurerTaft Communications732-233-4881michael.lauer@rfbinder.com

Related News